Monitoring Low Molecular Weight Heparins with antiXa Activity: House of Cards or Firm Foundation?

2003 ◽  
Vol 38 (3) ◽  
pp. 202-211 ◽  
Author(s):  
Gilles L. Fraser ◽  
Joe P. Mckenna
Keyword(s):  
Health Care ◽  
Molecular Weight ◽  
Drug Therapy ◽  
Critically Ill ◽  
Critically Ill Patient ◽  
Low Molecular Weight ◽  
Low Molecular Weight Heparins ◽  
Icu Patients ◽  
House Of Cards ◽  
The Impact

This feature examines the impact of pharmacologic interventions on the treatment of the critically ill patient — an area of health care that has become increasingly complex. It will review recent advances (including evolving and controversial data) in drug therapy for adult ICU patients and assess these new modalities in terms of clinical, humanistic, and economic outcomes.

Advances and Controversies in Adult ICU Sedation, Part 1: An Overview of the Importance of Sedation and Agitation and Subjective Assessment Tools for Patient Evaluation

2001 ◽  
Vol 36 (12) ◽  
pp. 1266-1278
Author(s):  
Gilles L. Fraser ◽  
Richard Riker
Keyword(s):  
Health Care ◽  
Drug Therapy ◽  
Critically Ill ◽  
Subjective Assessment ◽  
Assessment Tools ◽  
Critically Ill Patient ◽  
Patient Evaluation ◽  
Icu Patients ◽  
Icu Sedation ◽  
The Impact

This feature examines the impact of pharmacologic interventions on the treatment of the critically ill patient—an area of health care that has become increasingly complex. It will review recent advances (including evolving and controversial data) in drug therapy for adult ICU patients and assess these new modalities in terms of clinical, humanistic, and economic outcomes. Direct questions or comments to Gil Fraser, PharmD, at [email protected] .

Behavioral Effects of ICU Medications

2005 ◽  
Vol 40 (5) ◽  
pp. 387-392
Author(s):  
Gil Fraser ◽  
Richard R. Riker
Keyword(s):  
Health Care ◽  
Drug Therapy ◽  
Critically Ill ◽  
Economic Outcomes ◽  
Behavioral Effects ◽  
Critically Ill Patient ◽  
Icu Patients ◽  
Recent Advances ◽  
The Impact

This feature examines the impact of pharmacologic interventions on the treatment of the critically ill patient — an area of health care that has become increasingly complex. Recent advances in drug therapy for adult ICU patients (including evolving and controversial data) will be reviewed and assessed in terms of clinical, humanistic, and economic outcomes. Direct questions or comments to Gil Fraser, PharmD, at [email protected] .

Early Treatment with Fluconazole in Adult ICU Patients at High Risk for Severe Candidiasis

2002 ◽  
Vol 37 (9) ◽  
pp. 928-935 ◽  
Author(s):  
Jason A. Yahwak ◽  
Gilles L. Fraser
Keyword(s):  
Health Care ◽  
Drug Therapy ◽  
High Risk ◽  
Critically Ill ◽  
Early Treatment ◽  
Economic Outcomes ◽  
Critically Ill Patient ◽  
Icu Patients ◽  
Recent Advances ◽  
The Impact

This feature examines the impact of pharmacologic interventions on the treatment of the critically ill patient–an area of health care that has become increasingly complex. It will review recent advances (including evolving and controversial data) in drug therapy for adult ICU patients and assess these new modalities in terms of clinical, humanistic, and economic outcomes.

Important Changes in the ACLS 2000 Guidelines for the Management of Cardiac Arrest

2002 ◽  
Vol 37 (5) ◽  
pp. 469-473 ◽  
Author(s):  
Gilles L. Fraser ◽  
Sandra P. Bagwell
Keyword(s):  
Health Care ◽  
Cardiac Arrest ◽  
Drug Therapy ◽  
Critically Ill ◽  
Economic Outcomes ◽  
Critically Ill Patient ◽  
Icu Patients ◽  
Recent Advances ◽  
The Impact

This feature examines the impact of pharmacologic interventions on the treatment of the critically ill patient—an area of health care that has become increasingly complex. It will review recent advances (including evolving and controversial data) in drug therapy for adult ICU patients and assess these new modalities in terms of clinical, humanistic, and economic outcomes.

Advances and Controversies in Adult ICU Sedation, Part 3: Evolving Pharmacological Treatment Issues

2002 ◽  
Vol 37 (4) ◽  
pp. 362-368 ◽  
Author(s):  
Gilles L. Fraser ◽  
Richard Riker
Keyword(s):  
Health Care ◽  
Drug Therapy ◽  
Critically Ill ◽  
Pharmacological Treatment ◽  
Economic Outcomes ◽  
Critically Ill Patient ◽  
Icu Patients ◽  
Recent Advances ◽  
Icu Sedation ◽  
The Impact

This feature examines the impact of pharmacologic interventions on the treatment of the critically ill patient—an area of health care that has become increasingly complex. It will review recent advances (including evolving and controversial data) in drug therapy for adult ICU patients and assess these new modalities in terms of clinical, humanistic, and economic outcomes.

Pharmacotherapy for Alcohol Withdrawal

2003 ◽  
Vol 38 (5) ◽  
pp. 420-425 ◽  
Author(s):  
Brian M. Hodges
Keyword(s):  
Health Care ◽  
Drug Therapy ◽  
Critically Ill ◽  
Alcohol Withdrawal ◽  
Economic Outcomes ◽  
Critically Ill Patient ◽  
Icu Patients ◽  
Recent Advances ◽  
The Impact

This feature examines the impact of pharmacologic interventions on the treatment of the critically ill patient — an area of health care that has become increasingly complex. Recent advances in drug therapy for adult ICU patients (including evolving and controversial data) will be reviewed and assessed in terms of clinical, humanistic, and economic outcomes. Direct questions or comments to Gil Fraser, PharmD, at [email protected] .

The Uncertain Risk of Single-Dose Etomidate in the Critically III

2005 ◽  
Vol 40 (8) ◽  
pp. 658-661 ◽  
Author(s):  
Gilles L. Fraser ◽  
Richard R. Riker
Keyword(s):  
Health Care ◽  
Single Dose ◽  
Drug Therapy ◽  
Critically Ill ◽  
Economic Outcomes ◽  
Critically Ill Patient ◽  
Icu Patients ◽  
Recent Advances ◽  
The Impact

This feature examines the impact of pharmacologic interventions on the treatment of the critically ill patient — an area of health care that has become increasingly complex. Recent advances in drug therapy for adult ICU patients (including evolving and controversial data) will be reviewed and assessed in terms of clinical, humanistic, and economic outcomes. Direct questions or comments to Gil Fraser, PharmD, at [email protected] .

Vasopressin for Vasodilatory Shock

2002 ◽  
Vol 37 (11) ◽  
pp. 1149-1157 ◽  
Author(s):  
Brian M. Hodges ◽  
Gilles Fraser
Keyword(s):  
Health Care ◽  
Drug Therapy ◽  
Critically Ill ◽  
Economic Outcomes ◽  
Critically Ill Patient ◽  
Vasodilatory Shock ◽  
Icu Patients ◽  
Recent Advances ◽  
The Impact

This feature examines the impact of pharmacologic interventions on the treatment of the critically ill patient–an area of health care that has become increasingly complex. It will review recent advances (including evolving and controversial data) in drug therapy for adult ICU patients and assess these new modalities in terms of clinical, humanistic, and economic outcomes. Direct questions or comments to Gil Fraser, PharmD, at [email protected] .

Corticosteroids in ARDS: The Never-Ending Story

2007 ◽  
Vol 42 (8) ◽  
pp. 691-701 ◽  
Author(s):  
Zachariah Thomas ◽  
Katarzyna Kimborowicz
Keyword(s):  
Health Care ◽  
Intensive Care Unit ◽  
Intensive Care ◽  
Drug Therapy ◽  
Critically Ill ◽  
Economic Outcomes ◽  
Critically Ill Patient ◽  
Adult Intensive Care Unit ◽  
Recent Advances ◽  
The Impact

This feature examines the impact of pharmacologic interventions on the treatment of the critically ill patient — an area of health care that has become increasingly complex. Recent advances in drug therapy (including evolving and controversial data) for adult intensive-care-unit patients will be reviewed and assessed in terms of clinical, humanistic, and economic outcomes.

Pharmacologic and Liability Considerations of Therapeutic Interchange with Low-Molecular-Weight Heparins

2003 ◽  
Vol 38 (7) ◽  
pp. 652-658 ◽  
Author(s):  
Carl Gainor ◽  
Gordon J Vanscoy ◽  
Cynthia S Niccolai ◽  
Thomas L Rihn
Keyword(s):  
Health Care ◽  
Molecular Weight ◽  
Health Care Systems ◽  
Low Molecular Weight ◽  
Low Molecular Weight Heparins ◽  
Medication Costs ◽  
Formulary Management ◽  
Frequent Use ◽  
Care Systems ◽  
Therapeutic Interchange

Therapeutic interchange (TI), a formulary management process, is used by health care systems to help contain medication costs. A scientifically defensible and pharmacoeconomically beneficial TI program adheres to rigorous criteria enforced by an institution's Pharmacy and Therapeutics Committee. In situations where adherence to essential criteria is not mandated, TI may not produce the intended clinical and economic outcomes, and in practice may have legal implications. Appropriate application of TI has been described within the position statements of certain health care organizations and associations. Due to the high cost and frequent use of low-molecular-weight heparins (LMWHs), health care institutions have identified this pharmacologic class as a potential target for TI. Currently, the application of the TI process to LMWHs is questionable. This paper reviews the TI process and explores its controversial role in the formulary management of LMWHs.

Sign in / Sign up

Export Citation Format

Share Document